Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 1;96(2):174-178.
doi: 10.1002/ajh.26059. Epub 2020 Dec 30.

Covid-19 will not "magically disappear": Why access to widespread testing is paramount

Paul E George  1   2 , Claire L Stokes  2 , Leda C Bassit  2   3   4   5 , Ann Chahroudi  2   5 , Janet Figueroa  2   5 , Mark A Griffiths  2   4 , Stacy Heilman  2   5 , David N Ku  5   6 , Eric J Nehl  5   7   8 , Traci Leong  5   7 , Joshua M Levy  2   5 , Russell Kempker  2   5 , Robert G Mannino  1   2   5   9 , Maud Mavigner  2   5   10 , Sunita I Park  4   5   11 , Anuradha Rao  2   5 , Paulina A Rebolledo  2   5   7 , John D Roback  2   5   12 , Beverly B Rogers  2   4   5 , Raymond F Schinazi  2   3   4   5 , Julie Sullivan  2   5 , Erika A Tyburski  1   2   5   9 , Miriam B Vos  2   5   12 , Jesse J Waggoner  2   5 , Yun F Wang  2   5 , Jen Madsen  13 , Daniel S Wechsler  1   2 , Clinton H Joiner  1   2 , Greg S Martin  2   5 , Wilbur A Lam  1   2   5   9
Affiliations

Covid-19 will not "magically disappear": Why access to widespread testing is paramount

Paul E George et al. Am J Hematol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
As testing capacity increased, Children's Healthcare of Atlanta (CHOA) changed testing policy to include asymptomatic (Heme Asx) testing prior to surgery and symptomatic (Heme sx) testing of patients with atypical Covid‐19 presentations such as fever and neutropenia or admission for a sickle cell crisis [Color figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. McFadyen JD, Hannah S, Karlheinz P. The emerging threat of (micro)thrombosis in COVID‐19 and its therapeutic implications. Circ Res. 2020;127(4):571‐587. 10.1161/CIRCRESAHA.120.317447. - DOI - PMC - PubMed
    1. Connors JM, Levy JH. COVID‐19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033‐2040. 10.1182/blood.2020006000. - DOI - PMC - PubMed
    1. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(5):1023‐1026. 10.1111/jth.14810. - DOI - PMC - PubMed
    1. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334‐346. 10.1056/NEJMoa2021680. - DOI - PMC - PubMed
    1. Tromberg BJ, Schwetz TA, Pérez‐Stable EJ, et al. Rapid scaling up of Covid‐19 diagnostic testing in the United States — The NIH RADx initiative. N Engl J Med. 2020;383(11):1071‐1077. 10.1056/NEJMsr2022263. - DOI - PMC - PubMed

Publication types

MeSH terms